How will ITMN-191 differentiate itself among PIs?
Ghmm, you may best be able to answer this as I know you have the RMF for ITMN. I'm just curious what the consensus is on how ITMN-191 will be able to differentiate itself from the other HCV PIs. The compound clearly won't be first-in-class, barring a setback from telaprevir or boceprevir in Phase III. Also, I don't know if the compound will be a best-in-class either as I assume it's more of a first generation PI. The second generation PIs expect to improve upon the first with greater potency, which would allow co-formulation down the road, and presumably a greater safety margin.
What are your thoughts on this? Do you believe ITMN-191 already incorporates attributes of the second generation PIs? Or are you more or less counting on the fact that ITMN-191 is ahead of those second generation PIs in the clinic and should therefore have some time on the market to itself along with the other first generation PIs?
Market Data 
Markets 
AI
